nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Clonidine—SLC22A3—germ cell cancer	0.0564	1	CrCbGaD
Apraclonidine—Ocular discomfort—Methotrexate—germ cell cancer	0.0267	0.0283	CcSEcCtD
Apraclonidine—Photophobia—Vinblastine—germ cell cancer	0.0167	0.0177	CcSEcCtD
Apraclonidine—Eye irritation—Ifosfamide—germ cell cancer	0.015	0.0159	CcSEcCtD
Apraclonidine—Rhinorrhoea—Cisplatin—germ cell cancer	0.0136	0.0145	CcSEcCtD
Apraclonidine—Inflammation—Ifosfamide—germ cell cancer	0.0132	0.014	CcSEcCtD
Apraclonidine—Inflammation—Etoposide—germ cell cancer	0.0104	0.0111	CcSEcCtD
Apraclonidine—Haemorrhage—Vinblastine—germ cell cancer	0.00892	0.00946	CcSEcCtD
Apraclonidine—Pharyngitis—Vinblastine—germ cell cancer	0.00886	0.00939	CcSEcCtD
Apraclonidine—Face oedema—Cisplatin—germ cell cancer	0.00775	0.00821	CcSEcCtD
Apraclonidine—Irritability—Cisplatin—germ cell cancer	0.00766	0.00812	CcSEcCtD
Apraclonidine—Haemorrhage—Bleomycin—germ cell cancer	0.00754	0.00799	CcSEcCtD
Apraclonidine—Ill-defined disorder—Vinblastine—germ cell cancer	0.00721	0.00764	CcSEcCtD
Apraclonidine—Nasopharyngitis—Cisplatin—germ cell cancer	0.00718	0.00761	CcSEcCtD
Apraclonidine—Infestation NOS—Ifosfamide—germ cell cancer	0.00718	0.0076	CcSEcCtD
Apraclonidine—Infestation—Ifosfamide—germ cell cancer	0.00718	0.0076	CcSEcCtD
Apraclonidine—Malaise—Vinblastine—germ cell cancer	0.00701	0.00742	CcSEcCtD
Apraclonidine—Pharyngitis—Dactinomycin—germ cell cancer	0.00698	0.00739	CcSEcCtD
Apraclonidine—Conjunctivitis—Ifosfamide—germ cell cancer	0.00697	0.00739	CcSEcCtD
Apraclonidine—Abdominal discomfort—Cisplatin—germ cell cancer	0.00665	0.00705	CcSEcCtD
Apraclonidine—Erythema—Bleomycin—germ cell cancer	0.00656	0.00695	CcSEcCtD
Apraclonidine—Bradycardia—Ifosfamide—germ cell cancer	0.00656	0.00695	CcSEcCtD
Apraclonidine—Discomfort—Vinblastine—germ cell cancer	0.00653	0.00692	CcSEcCtD
Apraclonidine—Haemorrhage—Ifosfamide—germ cell cancer	0.00644	0.00683	CcSEcCtD
Apraclonidine—Inflammation—Methotrexate—germ cell cancer	0.00626	0.00663	CcSEcCtD
Apraclonidine—Visual impairment—Ifosfamide—germ cell cancer	0.00621	0.00658	CcSEcCtD
Apraclonidine—Erythema—Dactinomycin—germ cell cancer	0.00612	0.00648	CcSEcCtD
Apraclonidine—Ill-defined disorder—Bleomycin—germ cell cancer	0.00609	0.00645	CcSEcCtD
Apraclonidine—Eye disorder—Ifosfamide—germ cell cancer	0.00602	0.00638	CcSEcCtD
Apraclonidine—Conjunctivitis—Cisplatin—germ cell cancer	0.00601	0.00637	CcSEcCtD
Apraclonidine—Malaise—Bleomycin—germ cell cancer	0.00592	0.00627	CcSEcCtD
Apraclonidine—Angiopathy—Ifosfamide—germ cell cancer	0.00584	0.00619	CcSEcCtD
Apraclonidine—Mediastinal disorder—Ifosfamide—germ cell cancer	0.00581	0.00615	CcSEcCtD
Apraclonidine—Arrhythmia—Ifosfamide—germ cell cancer	0.00575	0.0061	CcSEcCtD
Apraclonidine—Paraesthesia—Vinblastine—germ cell cancer	0.00569	0.00603	CcSEcCtD
Apraclonidine—Ill-defined disorder—Dactinomycin—germ cell cancer	0.00568	0.00602	CcSEcCtD
Apraclonidine—Infestation—Etoposide—germ cell cancer	0.00567	0.00601	CcSEcCtD
Apraclonidine—Infestation NOS—Etoposide—germ cell cancer	0.00567	0.00601	CcSEcCtD
Apraclonidine—Bradycardia—Cisplatin—germ cell cancer	0.00565	0.00599	CcSEcCtD
Apraclonidine—Mental disorder—Ifosfamide—germ cell cancer	0.00564	0.00598	CcSEcCtD
Apraclonidine—Erythema—Ifosfamide—germ cell cancer	0.00561	0.00594	CcSEcCtD
Apraclonidine—Chest pain—Bleomycin—germ cell cancer	0.00559	0.00592	CcSEcCtD
Apraclonidine—Myalgia—Bleomycin—germ cell cancer	0.00559	0.00592	CcSEcCtD
Apraclonidine—Discomfort—Bleomycin—germ cell cancer	0.00552	0.00585	CcSEcCtD
Apraclonidine—Malaise—Dactinomycin—germ cell cancer	0.00552	0.00585	CcSEcCtD
Apraclonidine—Constipation—Vinblastine—germ cell cancer	0.00542	0.00575	CcSEcCtD
Apraclonidine—Pain—Vinblastine—germ cell cancer	0.00542	0.00575	CcSEcCtD
Apraclonidine—Oedema—Bleomycin—germ cell cancer	0.00535	0.00567	CcSEcCtD
Apraclonidine—Visual impairment—Cisplatin—germ cell cancer	0.00535	0.00567	CcSEcCtD
Apraclonidine—Infection—Bleomycin—germ cell cancer	0.00532	0.00564	CcSEcCtD
Apraclonidine—Vision blurred—Ifosfamide—germ cell cancer	0.00528	0.0056	CcSEcCtD
Apraclonidine—Feeling abnormal—Vinblastine—germ cell cancer	0.00522	0.00554	CcSEcCtD
Apraclonidine—Myalgia—Dactinomycin—germ cell cancer	0.00521	0.00552	CcSEcCtD
Apraclonidine—Ill-defined disorder—Ifosfamide—germ cell cancer	0.0052	0.00551	CcSEcCtD
Apraclonidine—Eye disorder—Cisplatin—germ cell cancer	0.00519	0.0055	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Vinblastine—germ cell cancer	0.00518	0.00549	CcSEcCtD
Apraclonidine—Discomfort—Dactinomycin—germ cell cancer	0.00515	0.00545	CcSEcCtD
Apraclonidine—Malaise—Ifosfamide—germ cell cancer	0.00506	0.00536	CcSEcCtD
Apraclonidine—Abdominal pain—Vinblastine—germ cell cancer	0.00501	0.00531	CcSEcCtD
Apraclonidine—Mediastinal disorder—Cisplatin—germ cell cancer	0.005	0.0053	CcSEcCtD
Apraclonidine—Oedema—Dactinomycin—germ cell cancer	0.00499	0.00529	CcSEcCtD
Apraclonidine—Infection—Dactinomycin—germ cell cancer	0.00496	0.00526	CcSEcCtD
Apraclonidine—Arrhythmia—Cisplatin—germ cell cancer	0.00496	0.00526	CcSEcCtD
Apraclonidine—Palpitations—Ifosfamide—germ cell cancer	0.00496	0.00525	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Bleomycin—germ cell cancer	0.00488	0.00517	CcSEcCtD
Apraclonidine—Erythema—Cisplatin—germ cell cancer	0.00483	0.00512	CcSEcCtD
Apraclonidine—Paraesthesia—Bleomycin—germ cell cancer	0.00481	0.0051	CcSEcCtD
Apraclonidine—Dyspnoea—Bleomycin—germ cell cancer	0.00477	0.00506	CcSEcCtD
Apraclonidine—Chest pain—Ifosfamide—germ cell cancer	0.00477	0.00506	CcSEcCtD
Apraclonidine—Myalgia—Ifosfamide—germ cell cancer	0.00477	0.00506	CcSEcCtD
Apraclonidine—Eye disorder—Etoposide—germ cell cancer	0.00475	0.00504	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—germ cell cancer	0.00474	0.00502	CcSEcCtD
Apraclonidine—Discomfort—Ifosfamide—germ cell cancer	0.00472	0.005	CcSEcCtD
Apraclonidine—Hypersensitivity—Vinblastine—germ cell cancer	0.00467	0.00495	CcSEcCtD
Apraclonidine—Angiopathy—Etoposide—germ cell cancer	0.00462	0.00489	CcSEcCtD
Apraclonidine—Mediastinal disorder—Etoposide—germ cell cancer	0.00458	0.00486	CcSEcCtD
Apraclonidine—Pain—Bleomycin—germ cell cancer	0.00458	0.00485	CcSEcCtD
Apraclonidine—Oedema—Ifosfamide—germ cell cancer	0.00458	0.00485	CcSEcCtD
Apraclonidine—Vision blurred—Cisplatin—germ cell cancer	0.00456	0.00483	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Dactinomycin—germ cell cancer	0.00455	0.00482	CcSEcCtD
Apraclonidine—Asthenia—Vinblastine—germ cell cancer	0.00455	0.00482	CcSEcCtD
Apraclonidine—Infection—Ifosfamide—germ cell cancer	0.00455	0.00482	CcSEcCtD
Apraclonidine—Nervous system disorder—Ifosfamide—germ cell cancer	0.00449	0.00476	CcSEcCtD
Apraclonidine—Ill-defined disorder—Cisplatin—germ cell cancer	0.00449	0.00475	CcSEcCtD
Apraclonidine—Skin disorder—Ifosfamide—germ cell cancer	0.00444	0.00471	CcSEcCtD
Apraclonidine—Feeling abnormal—Bleomycin—germ cell cancer	0.00441	0.00468	CcSEcCtD
Apraclonidine—Malaise—Cisplatin—germ cell cancer	0.00436	0.00462	CcSEcCtD
Apraclonidine—Diarrhoea—Vinblastine—germ cell cancer	0.00434	0.0046	CcSEcCtD
Apraclonidine—Dysgeusia—Etoposide—germ cell cancer	0.00434	0.0046	CcSEcCtD
Apraclonidine—Fatigue—Dactinomycin—germ cell cancer	0.00431	0.00456	CcSEcCtD
Apraclonidine—Pain—Dactinomycin—germ cell cancer	0.00427	0.00453	CcSEcCtD
Apraclonidine—Irritability—Methotrexate—germ cell cancer	0.0042	0.00446	CcSEcCtD
Apraclonidine—Dizziness—Vinblastine—germ cell cancer	0.00419	0.00444	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Ifosfamide—germ cell cancer	0.00417	0.00442	CcSEcCtD
Apraclonidine—Myalgia—Cisplatin—germ cell cancer	0.00412	0.00436	CcSEcCtD
Apraclonidine—Feeling abnormal—Dactinomycin—germ cell cancer	0.00412	0.00436	CcSEcCtD
Apraclonidine—Paraesthesia—Ifosfamide—germ cell cancer	0.00411	0.00435	CcSEcCtD
Apraclonidine—Ill-defined disorder—Etoposide—germ cell cancer	0.00411	0.00435	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—germ cell cancer	0.00409	0.00433	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Dactinomycin—germ cell cancer	0.00408	0.00433	CcSEcCtD
Apraclonidine—Dyspnoea—Ifosfamide—germ cell cancer	0.00408	0.00432	CcSEcCtD
Apraclonidine—Somnolence—Ifosfamide—germ cell cancer	0.00407	0.00431	CcSEcCtD
Apraclonidine—Discomfort—Cisplatin—germ cell cancer	0.00407	0.00431	CcSEcCtD
Apraclonidine—Vomiting—Vinblastine—germ cell cancer	0.00403	0.00427	CcSEcCtD
Apraclonidine—Malaise—Etoposide—germ cell cancer	0.00399	0.00423	CcSEcCtD
Apraclonidine—Headache—Vinblastine—germ cell cancer	0.00397	0.00421	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Ifosfamide—germ cell cancer	0.00395	0.00419	CcSEcCtD
Apraclonidine—Abdominal pain—Dactinomycin—germ cell cancer	0.00395	0.00418	CcSEcCtD
Apraclonidine—Fatigue—Ifosfamide—germ cell cancer	0.00395	0.00418	CcSEcCtD
Apraclonidine—Oedema—Cisplatin—germ cell cancer	0.00395	0.00418	CcSEcCtD
Apraclonidine—Hypersensitivity—Bleomycin—germ cell cancer	0.00394	0.00418	CcSEcCtD
Apraclonidine—Infection—Cisplatin—germ cell cancer	0.00392	0.00415	CcSEcCtD
Apraclonidine—Pain—Ifosfamide—germ cell cancer	0.00391	0.00415	CcSEcCtD
Apraclonidine—Constipation—Ifosfamide—germ cell cancer	0.00391	0.00415	CcSEcCtD
Apraclonidine—Nervous system disorder—Cisplatin—germ cell cancer	0.00387	0.0041	CcSEcCtD
Apraclonidine—Asthenia—Bleomycin—germ cell cancer	0.00384	0.00407	CcSEcCtD
Apraclonidine—Skin disorder—Cisplatin—germ cell cancer	0.00383	0.00406	CcSEcCtD
Apraclonidine—Asthma—Methotrexate—germ cell cancer	0.00381	0.00403	CcSEcCtD
Apraclonidine—Pruritus—Bleomycin—germ cell cancer	0.00379	0.00401	CcSEcCtD
Apraclonidine—Feeling abnormal—Ifosfamide—germ cell cancer	0.00377	0.004	CcSEcCtD
Apraclonidine—Chest pain—Etoposide—germ cell cancer	0.00377	0.004	CcSEcCtD
Apraclonidine—Nausea—Vinblastine—germ cell cancer	0.00377	0.00399	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—germ cell cancer	0.00374	0.00397	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Ifosfamide—germ cell cancer	0.00374	0.00397	CcSEcCtD
Apraclonidine—Discomfort—Etoposide—germ cell cancer	0.00373	0.00395	CcSEcCtD
Apraclonidine—Hypersensitivity—Dactinomycin—germ cell cancer	0.00368	0.0039	CcSEcCtD
Apraclonidine—Abdominal discomfort—Methotrexate—germ cell cancer	0.00365	0.00387	CcSEcCtD
Apraclonidine—Abdominal pain—Ifosfamide—germ cell cancer	0.00362	0.00383	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Cisplatin—germ cell cancer	0.00359	0.00381	CcSEcCtD
Apraclonidine—Infection—Etoposide—germ cell cancer	0.00359	0.00381	CcSEcCtD
Apraclonidine—Asthenia—Dactinomycin—germ cell cancer	0.00358	0.0038	CcSEcCtD
Apraclonidine—Paraesthesia—Cisplatin—germ cell cancer	0.00354	0.00375	CcSEcCtD
Apraclonidine—Dyspnoea—Cisplatin—germ cell cancer	0.00352	0.00373	CcSEcCtD
Apraclonidine—Skin disorder—Etoposide—germ cell cancer	0.00351	0.00372	CcSEcCtD
Apraclonidine—Diarrhoea—Dactinomycin—germ cell cancer	0.00342	0.00362	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Cisplatin—germ cell cancer	0.00341	0.00361	CcSEcCtD
Apraclonidine—Vomiting—Bleomycin—germ cell cancer	0.0034	0.00361	CcSEcCtD
Apraclonidine—Infestation NOS—Methotrexate—germ cell cancer	0.00339	0.0036	CcSEcCtD
Apraclonidine—Infestation—Methotrexate—germ cell cancer	0.00339	0.0036	CcSEcCtD
Apraclonidine—Pain—Cisplatin—germ cell cancer	0.00337	0.00358	CcSEcCtD
Apraclonidine—Dermatitis—Bleomycin—germ cell cancer	0.00337	0.00357	CcSEcCtD
Apraclonidine—Hypersensitivity—Ifosfamide—germ cell cancer	0.00337	0.00357	CcSEcCtD
Apraclonidine—Conjunctivitis—Methotrexate—germ cell cancer	0.0033	0.0035	CcSEcCtD
Apraclonidine—Asthenia—Ifosfamide—germ cell cancer	0.00328	0.00348	CcSEcCtD
Apraclonidine—Feeling abnormal—Cisplatin—germ cell cancer	0.00325	0.00345	CcSEcCtD
Apraclonidine—Paraesthesia—Etoposide—germ cell cancer	0.00325	0.00344	CcSEcCtD
Apraclonidine—Pruritus—Ifosfamide—germ cell cancer	0.00324	0.00343	CcSEcCtD
Apraclonidine—Dyspnoea—Etoposide—germ cell cancer	0.00322	0.00341	CcSEcCtD
Apraclonidine—Somnolence—Etoposide—germ cell cancer	0.00321	0.00341	CcSEcCtD
Apraclonidine—Nausea—Bleomycin—germ cell cancer	0.00318	0.00337	CcSEcCtD
Apraclonidine—Vomiting—Dactinomycin—germ cell cancer	0.00318	0.00337	CcSEcCtD
Apraclonidine—Diarrhoea—Ifosfamide—germ cell cancer	0.00313	0.00332	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Etoposide—germ cell cancer	0.00312	0.00331	CcSEcCtD
Apraclonidine—Fatigue—Etoposide—germ cell cancer	0.00312	0.0033	CcSEcCtD
Apraclonidine—Pain—Etoposide—germ cell cancer	0.00309	0.00328	CcSEcCtD
Apraclonidine—Constipation—Etoposide—germ cell cancer	0.00309	0.00328	CcSEcCtD
Apraclonidine—Haemorrhage—Methotrexate—germ cell cancer	0.00305	0.00323	CcSEcCtD
Apraclonidine—Dizziness—Ifosfamide—germ cell cancer	0.00303	0.00321	CcSEcCtD
Apraclonidine—Pharyngitis—Methotrexate—germ cell cancer	0.00302	0.00321	CcSEcCtD
Apraclonidine—Feeling abnormal—Etoposide—germ cell cancer	0.00298	0.00316	CcSEcCtD
Apraclonidine—Nausea—Dactinomycin—germ cell cancer	0.00297	0.00314	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Etoposide—germ cell cancer	0.00296	0.00313	CcSEcCtD
Apraclonidine—Visual impairment—Methotrexate—germ cell cancer	0.00294	0.00311	CcSEcCtD
Apraclonidine—Vomiting—Ifosfamide—germ cell cancer	0.00291	0.00308	CcSEcCtD
Apraclonidine—Hypersensitivity—Cisplatin—germ cell cancer	0.00291	0.00308	CcSEcCtD
Apraclonidine—Dermatitis—Ifosfamide—germ cell cancer	0.00288	0.00306	CcSEcCtD
Apraclonidine—Abdominal pain—Etoposide—germ cell cancer	0.00286	0.00303	CcSEcCtD
Apraclonidine—Eye disorder—Methotrexate—germ cell cancer	0.00285	0.00302	CcSEcCtD
Apraclonidine—Asthenia—Cisplatin—germ cell cancer	0.00283	0.003	CcSEcCtD
Apraclonidine—Angiopathy—Methotrexate—germ cell cancer	0.00276	0.00293	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methotrexate—germ cell cancer	0.00275	0.00291	CcSEcCtD
Apraclonidine—Nausea—Ifosfamide—germ cell cancer	0.00272	0.00288	CcSEcCtD
Apraclonidine—Diarrhoea—Cisplatin—germ cell cancer	0.0027	0.00286	CcSEcCtD
Apraclonidine—Mental disorder—Methotrexate—germ cell cancer	0.00267	0.00283	CcSEcCtD
Apraclonidine—Hypersensitivity—Etoposide—germ cell cancer	0.00266	0.00282	CcSEcCtD
Apraclonidine—Erythema—Methotrexate—germ cell cancer	0.00265	0.00281	CcSEcCtD
Apraclonidine—Dysgeusia—Methotrexate—germ cell cancer	0.0026	0.00275	CcSEcCtD
Apraclonidine—Asthenia—Etoposide—germ cell cancer	0.00259	0.00275	CcSEcCtD
Apraclonidine—Pruritus—Etoposide—germ cell cancer	0.00256	0.00271	CcSEcCtD
Apraclonidine—Vomiting—Cisplatin—germ cell cancer	0.00251	0.00266	CcSEcCtD
Apraclonidine—Vision blurred—Methotrexate—germ cell cancer	0.0025	0.00265	CcSEcCtD
Apraclonidine—Dermatitis—Cisplatin—germ cell cancer	0.00249	0.00263	CcSEcCtD
Apraclonidine—Diarrhoea—Etoposide—germ cell cancer	0.00247	0.00262	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methotrexate—germ cell cancer	0.00246	0.00261	CcSEcCtD
Apraclonidine—Malaise—Methotrexate—germ cell cancer	0.00239	0.00254	CcSEcCtD
Apraclonidine—Dizziness—Etoposide—germ cell cancer	0.00239	0.00253	CcSEcCtD
Apraclonidine—Nausea—Cisplatin—germ cell cancer	0.00234	0.00248	CcSEcCtD
Apraclonidine—Vomiting—Etoposide—germ cell cancer	0.0023	0.00244	CcSEcCtD
Apraclonidine—Dermatitis—Etoposide—germ cell cancer	0.00228	0.00241	CcSEcCtD
Apraclonidine—Headache—Etoposide—germ cell cancer	0.00226	0.0024	CcSEcCtD
Apraclonidine—Chest pain—Methotrexate—germ cell cancer	0.00226	0.00239	CcSEcCtD
Apraclonidine—Myalgia—Methotrexate—germ cell cancer	0.00226	0.00239	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—germ cell cancer	0.00224	0.00238	CcSEcCtD
Apraclonidine—Discomfort—Methotrexate—germ cell cancer	0.00223	0.00236	CcSEcCtD
Apraclonidine—Infection—Methotrexate—germ cell cancer	0.00215	0.00228	CcSEcCtD
Apraclonidine—Nausea—Etoposide—germ cell cancer	0.00215	0.00228	CcSEcCtD
Apraclonidine—Nervous system disorder—Methotrexate—germ cell cancer	0.00212	0.00225	CcSEcCtD
Apraclonidine—Skin disorder—Methotrexate—germ cell cancer	0.0021	0.00223	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methotrexate—germ cell cancer	0.00197	0.00209	CcSEcCtD
Apraclonidine—Insomnia—Methotrexate—germ cell cancer	0.00196	0.00208	CcSEcCtD
Apraclonidine—Paraesthesia—Methotrexate—germ cell cancer	0.00194	0.00206	CcSEcCtD
Apraclonidine—Dyspnoea—Methotrexate—germ cell cancer	0.00193	0.00205	CcSEcCtD
Apraclonidine—Somnolence—Methotrexate—germ cell cancer	0.00192	0.00204	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Methotrexate—germ cell cancer	0.00187	0.00198	CcSEcCtD
Apraclonidine—Fatigue—Methotrexate—germ cell cancer	0.00187	0.00198	CcSEcCtD
Apraclonidine—Pain—Methotrexate—germ cell cancer	0.00185	0.00196	CcSEcCtD
Apraclonidine—Feeling abnormal—Methotrexate—germ cell cancer	0.00178	0.00189	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methotrexate—germ cell cancer	0.00177	0.00188	CcSEcCtD
Apraclonidine—Abdominal pain—Methotrexate—germ cell cancer	0.00171	0.00181	CcSEcCtD
Apraclonidine—Hypersensitivity—Methotrexate—germ cell cancer	0.0016	0.00169	CcSEcCtD
Apraclonidine—Asthenia—Methotrexate—germ cell cancer	0.00155	0.00165	CcSEcCtD
Apraclonidine—Pruritus—Methotrexate—germ cell cancer	0.00153	0.00162	CcSEcCtD
Apraclonidine—Diarrhoea—Methotrexate—germ cell cancer	0.00148	0.00157	CcSEcCtD
Apraclonidine—Dizziness—Methotrexate—germ cell cancer	0.00143	0.00152	CcSEcCtD
Apraclonidine—Vomiting—Methotrexate—germ cell cancer	0.00138	0.00146	CcSEcCtD
Apraclonidine—Dermatitis—Methotrexate—germ cell cancer	0.00136	0.00145	CcSEcCtD
Apraclonidine—Headache—Methotrexate—germ cell cancer	0.00136	0.00144	CcSEcCtD
Apraclonidine—Nausea—Methotrexate—germ cell cancer	0.00129	0.00136	CcSEcCtD
